China SXT Pharmaceuticals Working Capital Growth & History (SXTC)

China SXT Pharmaceuticals's working capital was $30.2M for fiscal 2026.

View full China SXT Pharmaceuticals company overview

China SXT Pharmaceuticals annual working capital history

China SXT Pharmaceuticals annual working capital

Fiscal yearPeriod endedWorking capitalChangeGrowth
20262026-03-31$30.2M$14.9M+97.33%
20252025-03-31$15.3M$10.0M+186.69%
20242024-03-31$5.3M$307,106+6.11%
20232023-03-31$5.0M−$305,981−5.74%
20222022-03-31$5.3M$676,717+14.54%
20212021-03-31$4.7M−$2.7M−36.88%
20202020-03-31$7.4M−$1.9M−20.45%
20192019-03-31$9.3M$7.5M+435.63%
20182018-03-31$1.7M

China SXT Pharmaceuticals working capital trends

Over the last five fiscal years, China SXT Pharmaceuticals's working capital increased from $4.7M to $30.2M, a change of $25.5M. The latest reported quarter, Q4 2026, shows $30.2M.

About the metric

What working capital means

Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.

Calculation and source

How working capital is calculated

TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review China SXT Pharmaceuticals source filings ↗

Community posts

It’s quiet here.

No posts about SXTC yet. Start the conversation.

Write the first post